Hyperion DeFi Inc

Análisis de la acción Hyperion DeFi Inc (HYPD)

$3.260

-0.324 (-9.94%)Al cierre

Loading chart…
High
3.695
Open
3.570
VWAP
3.40
Vol
1.01M
Mkt Cap
Low
3.240
Amount
3.42M
EV/EBITDA, TTM
-2.44

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles.

AI analysis of Hyperion DeFi Inc (HYPD)

buy

Hyperion DeFi Inc (HYPD) appears to be a good buy right now, especially considering its recent earnings report where it achieved an EPS of 0.92, indicating a strong recovery in profitability. Additionally, the stock has a forward P/E ratio of 0, suggesting it is undervalued relative to its earnings potential. The average analyst price target of $7.10 represents a potential upside of approximately 117% from the current price of $3.26, which is a significant incentive for long-term investors. However, the main risk is the recent volatility, as the stock experienced a 9.94% drop yesterday, highlighting potential instability in the short term.

Métricas de valoración

The current forward P/E ratio for Hyperion DeFi Inc (HYPD) is 0.00, compared to its 5-year average forward P/E of -0.57.

Forward P/E

Strongly Overvalued
5Y Average P/E
-0.57
Current P/E
0.00
Sobrevalorada
-0.41
Infravalorada
-0.73

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-0.71
Current EV/EBITDA
-2.44
Sobrevalorada
-0.23
Infravalorada
-1.18

Forward P/S

Fair
5Y Average P/S
14.60
Current P/S
18.68
Sobrevalorada
19.39
Infravalorada
9.81

Cronología de eventos

2026-07-23 (ET)

14:30:00

Hyperion DeFi Pioneers First-of-Its-Kind On-Chain Strategies

14:30:00

Hyperion DeFi CEO Discusses Business Model and Blockchain Infrastructure

2026-07-15 (ET)

13:30:00

Hyperion DeFi Enters HYPE Asset Use Agreement with Skew Technologies

2026-06-26 (ET)

10:01:00

ICE and OKX Form U.S. Crypto Joint Venture

2026-06-22 (ET)

12:00:00

Intercontinental Exchange and OKX Form 50-50 Joint Venture

Noticias

HYPD FAQ — answered by Alphio AI

Hyperion DeFi, Inc. is engaged in building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing simplified access to the Hyperliquid ecosystem. It is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers. It has launched its cryptocurrency treasury reserve, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid. Hyperliquid is a layer one blockchain (L1) written and optimized from first principles. It operates in the Healthcare sector.

Hyperion DeFi Inc (HYPD) appears to be a good buy right now, especially considering its recent earnings report where it achieved an EPS of 0.92, indicating a strong recovery in profitability. Additionally, the stock has a forward P/E ratio of 0, suggesting it is undervalued relative to its earnings potential. The average analyst price target of $7.10 represents a potential upside of approximately 117% from the current price of $3.26, which is a significant incentive for long-term investors. However, the main risk is the recent volatility, as the stock experienced a 9.94% drop yesterday, highlighting potential instability in the short term.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis